Overview of primary prevention of coronary heart disease and stroke
- Charles H Hennekens, MD, DrPH
Charles H Hennekens, MD, DrPH
- First Sir Richard Doll Professor & Senior Academic Advisor to the Dean, Charles E. Schmidt College of Medicine, Florida Atlantic University
- Clinical Professor, Nova Southeastern University
- Voluntary Professor, University of Miami Miller School of Medicine, Meharry Medical College, and Baylor Colle
- Section Editors
- Timothy O Lipman, MD
Timothy O Lipman, MD
- Section Editor — Nutrition
- GI-Hepatology-Nutrition Section
- Washington DC Veterans Affairs Medical Center
- Freek Verheugt, MD, FACC, FESC
Freek Verheugt, MD, FACC, FESC
- Section Editor — Coronary Heart Disease
- Onze Lieve Vrouwe Gasthuis, Netherlands
In the United States and most developed countries, despite remarkable declines in mortality, cardiovascular disease (CVD), which includes coronary heart disease, stroke, and peripheral artery disease, is and will remain, far and away, the leading cause of death in men and women .
An overview of the primary prevention of CVD is presented here, including a discussion of the additive benefits of risk factor reductions through therapeutic lifestyle changes and adjunctive drug therapies of proven benefit. Secondary prevention of CVD, emerging risk factors, and determining individual risk of a patient without known cardiovascular disease are discussed separately. (See "Prevention of cardiovascular disease events in those with established disease or at high risk" and "Overview of the risk equivalents and established risk factors for cardiovascular disease" and "Estimation of cardiovascular risk in an individual patient without known cardiovascular disease".)
In the United States (US), since 1975, cardiovascular disease (CVD) mortality has declined by 24 to 28 percent overall, among men and women, as well as black and whites, although men and blacks continue to experience far higher absolute mortality rates, especially at earlier ages, than their female and white counterparts. Further, the rate of decline has slowed since 1990 . It has been estimated that nearly half of the decline is due to earlier diagnosis and more aggressive treatment, especially of lipids and blood pressure and, particularly with adjunctive drug therapies of life saving benefit, which include statins, aspirin, angiotensin converting enzyme inhibitors and beta blockers . The remaining half of the decline in CVD mortality is attributable to favorable changes in therapeutic lifestyle changes, such as avoidance and cessation of cigarette smoking.
Despite these remarkable declines, however, CVD remains the leading cause of death in the US and has also become so worldwide. While continued improvement in diagnosis is desirable, modification of risk factor modification is a necessity. In descriptive data from a nationally representative survey, useful to formulate but not test hypotheses, five modifiable risk factors for CVD (elevated cholesterol, diabetes, hypertension, obesity, and smoking) accounted for one-half of CVD deaths in US adults aged 45 to 79 in 2009 to 2010 . The preventable fraction of CVD mortality associated with these risk factors was 54 percent for men and 50 percent for women.
The majority of the risk factors for CVD and stroke are modifiable by preventive measures, including therapeutic lifestyle changes and adjunctive drug therapies of proven benefit . In the descriptive INTERHEART study of patients from 52 countries, nine potentially modifiable factors accounted for over 90 percent of the population attributable risk of a first myocardial infarction (MI) . These included cigarette smoking, dyslipidemia, hypertension, diabetes, abdominal obesity, and psychosocial factors. In addition, factors that were associated with lowered risks included regular physical activity, daily consumption of fruits and vegetables, and daily consumption of small amounts of alcohol, which is likely to be about one drink for women and two for men.
- Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367:1747.
- Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999; 81:380.
- Capewell S, Beaglehole R, Seddon M, McMurray J. Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993. Circulation 2000; 102:1511.
- Patel SA, Winkel M, Ali MK, et al. Cardiovascular mortality associated with 5 leading risk factors: national and state preventable fractions estimated from survey data. Ann Intern Med 2015; 163:245.
- Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45:3754.
- Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937.
- Stampfer MJ, Hu FB, Manson JE, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343:16.
- Kurth T, Moore SC, Gaziano JM, et al. Healthy lifestyle and the risk of stroke in women. Arch Intern Med 2006; 166:1403.
- Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005; 365:434.
- Sotos-Prieto M, Bhupathiraju SN, Mattei J, et al. Changes in Diet Quality Scores and Risk of Cardiovascular Disease Among US Men and Women. Circulation 2015; 132:2212.
- LaCroix AZ, Lang J, Scherr P, et al. Smoking and mortality among older men and women in three communities. N Engl J Med 1991; 324:1619.
- Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380:581.
- Lewis SF, Hennekens CH. Regular Physical Activity: A 'Magic Bullet' for the Pandemics of Obesity and Cardiovascular Disease. Cardiology 2016; 134:360.
- Lewis SF, Hennekens CH. Regular Physical Activity: Forgotten Benefits. Am J Med 2016; 129:137.
- Manson JE, Hu FB, Rich-Edwards JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999; 341:650.
- Hennekens CH, Andreotti F. Leading avoidable cause of premature deaths worldwide: case for obesity. Am J Med 2013; 126:97.
- Hennekens CH, Andreotti F, Barice J. Metabolic Syndrome: The new silent killer. Gen Med Ed 2012; 1:28.
- Hennekens CH, Pfeffer MA, Newcomer JW, et al. Treatment of diabetes mellitus: the urgent need for multifactorial interventions. Am J Manag Care 2014; 20:357.
- Leening MJ, Berry JD, Allen NB. Lifetime Perspectives on Primary Prevention of Atherosclerotic Cardiovascular Disease. JAMA 2016; 315:1449.
- Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 2004; 292:1433.
- Akesson A, Larsson SC, Discacciati A, Wolk A. Low-risk diet and lifestyle habits in the primary prevention of myocardial infarction in men: a population-based prospective cohort study. J Am Coll Cardiol 2014; 64:1299.
- Chiuve SE, Rexrode KM, Spiegelman D, et al. Primary prevention of stroke by healthy lifestyle. Circulation 2008; 118:947.
- Castellano JM, Sanz G, Fernandez Ortiz A, et al. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. J Am Coll Cardiol 2014; 64:613.
- Lonn E, Bosch J, Teo KK, et al. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation 2010; 122:2078.
- de Cates AN, Farr MR, Wright N, et al. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev 2014; :CD009868.
- Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014; 348:g3318.
- Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol 2014; 64:2071.
- MAJOR COMPONENTS
- Healthy diet
- Smoking avoidance and cessation
- Hypertension control
- Physical activity
- Weight loss
- Management of type 2 diabetes
- Benefits and risks of small amounts of daily alcohol
- ADDITIVE BENEFITS OF RISK FACTOR REDUCTIONS
- Lifestyle changes
- SUMMARY AND RECOMMENDATIONS